Bronchial Carcinoma-Barran et al.
After more than two years there is one survivor out of four patients who underwent surgical resection after improving with preliminary treatment, whereas five out of eight having surgery without preliminary improvement survived two years and three are still alive. Again this difference could be pure chance. It could indicate that preliminary improvement on cytotoxic drugs was of no advantage or was harmful; but it was probably at least in part due to the fact that improvement with cytotoxic drugs occurred in patients with more rapidly growing and metastasizing tumours, which were therefore less amenable to curative resection.
The pulmonary-artery-perfusion group was planned because of a remarkable result that occurred previously in one out of 25 patients treated in this way. He was a 52-year-old man who at thoracotomy was found to have an advanced oat-cell growth invading the main vessels. Three weeks later he was given one dose of 17.5 mg. of nitrogen mustard by drip into the right main pulmonary artery. The next day he felt much better, and five days later the chest x-ray picture showed marked reduction in the shadowing due to the growth. Two weeks later the x-ray appearance had returned to normal and bronchoscopy confirmed the apparent complete resolution of the neoplasm. Four further perfusions were carried out during the next year and he remained well and at work for this period. Early recurrence was first suspected after 16 months, and deep x-ray therapy was given after 20 months. He survived for two and a half years.
One patient in the present series treated by pulmonary-artery perfusion with cyclophosphamide survived over 18 months, but this was a case of squamous-cell carcinoma and may well have been naturally slow-growing. There were no other responses worthy of remark.
The place of cytotoxic-drug therapy in the treatment of carcinoma of the bronchus remains controversial. The present series suggests that in about 50% of patients the tumour will recede to some extent during high-dosage treatment with cyclophosphamide. Poulsen's (1962 Poulsen's ( , 1963 findings of a higher one-year survival rate in patients with operable squamous-cell carcinomas treated with pre-operative and post-operative cyclophosphamide than in a controlled group having surgery alone encourages further research on these lines in the early cases.
With advanced disease the remissions are usually short, ranging from two to six months, but often they are worth while from the point of view of relief of distressing symptoms. It remains to be seen whether better results can be obtained with maintenance therapy or the combination of two or more different agents, and whether, when combined with x-ray therapy, summation or sensitizing effects can be obtained. Thalidomide is known to be relatively non-toxic (Somers, 1960) . If it also had immunosuppressive properties this would at once provide another aspect to explanations of its teratogenic action, and, at the same time, make it of considerable interest to those who seek to modify homograft rejection. To test whether it had any immunosuppressive properties its effect on the survival of mouse-skin homografts was examined. Mousestrain combinations with strong (C57BL-C3H/He) and with weaker (A-C3H/He) differences at the H-2 histocompatibility locus were used.
Summary
In previous experiments (to be published) it was found possible to modify the antigenic character of skin grafts by in vitro treatment prior to transplantation; thus rejection was obtained of syngeneic skin grafts previously incubated with allogeneic skin. Because of these findings some grafts were treated with thalidomide in vitro in the present experiments and some donors were given thalidomide before the grafts were excised.
Methods and Materials
The technique of skin-grafting did not differ significantly from that described by Billingham and Medawar (1951) except in the method of inducing anaesthesia. The mice each received intraperitoneally 0.1 ml. per 10 g. body weight of a freshly prepared 2.5% solution of bromethol (Avertin) in distilled water.
Full-thickness skin-grafts were taken from either C57BL or A strain female donors and transplanted to C3H/He female recipients suitably prepared.
Thalidomide as a suspension in 0.5% carboxymethyl cellulose (C.M.C. in normal saline) was made up freshly just before it was given intraperitoneally. Amounts of thalidomide varied in different experiments (see Table) , but the volume of C.M.C. in which they were given remained constant at 0.2 ml. Where recipients received post-operative thalidomide the first dose was administered on the day after skin-grafting, since even quite small doses were found to be toxic if given within 24 hours of bromethol administration. Dosage was continued daily until graft rejection was complete. The end-point for complete rejection was taken as that stage at which, on visual inspection, no viable graft tissue remained. Control animals received C.M.C. alone.
In some experiments, in addition to the recipients, the donors were also treated with thalidomide for varying periods before grafting. In other experiments the skin to be grafted was incubated for three hours in thalidomide (6 mg./100 ml.) in Krebs solution before transplantation. The Krebs solution had the following composition in g./l.: NaCl 6.9; KC1 0.35; KH2PO4 0.16; CaCl2.2H20 0.37; MgSO4.7H20 0.29 ; glucose 1.0; and NaHCO3 2.1, aerated constantly with 95 % oxygen and 5% carbon dioxide.
The animals were kept in groups of four or five and the bandages removed under anaesthesia 10 days after transplantation. The grafts were inspected daily until rejection was complete. The median survival times of the grafts are given together with their range. The median survival time is calculated as the time (in days) after transplantation at which 50% of the grafts have been completely rejected. The range gives the days on which the first and last grafts of a group were seen to have been completely rejected.
Results
The results of 15 experiments are given in the Table. The survival time of individual grafts in the control groups of both mouse-strain combinations was remarkably constant. In over 100 control transplantations from C57 to CH (approximately eight animals for each of the 13 experiments) graft survival never exceeded 11 days, and in 18 control transplantations from A to C3H (nine animals in each of two experiments) it was never more than 12 days. Complete rejection had thus occurred in both strain combinations within one to two days after removal of bandages.
When bandages were taken off, grafts on treated animals always appeared strikingly healthier and better healed than in those on controls in which often as many as half the animals in the group might already show signs of advanced graft rejection. In all treated animals, irrespective of the dosage scheme, rejection began later and advanced at a slower pace than in the controls. Rejection in controls was mostly complete within 12 to 24 hours; in the treated animals, on the other hand, the graft often broke up slowly into islands of viablelooking skin which took two to three days to disappear. Thalidomide seemed thus not only to slow down the onset of homograft rejection, but also to make it less violent when it occurred.
Where recipients were treated the median survival time of grafts was improved if donor skin was also treated either in vivo or in vitro prior to transplantation. The best result (Experiment 10) was obtained where several days' treatment with thalidomide before transplantation of both donors and recipients was continued post-operatively in the recipients.
Treatment of donors alone (Experiments 6, 13, and 14) gave only a slight prolongation of graft survival, and treatment of recipients alone (Experiments 1, 2 to that found with cyclophosphamide (Fox, 1964) and better than that found with Amethopterin (methotrexate) (Medawar, 1963) or mercaptopurine (Meeker et al., 1960) . The mechanism by which thalidomide produces prolongation of skin-graft survival is not clear. It may be through a direct immun-osuppressant action on the lymphoid system, though this is rendered less likely by the finding (see Table) that treatment of the donor before transplantation as well as the recipient increases length of graft survival. It seems more probable that, if a specific effect on the immune system is involved, thalidomide modifies the donor skin antigen or its recognition.
The findings of Roath et al. (1962 Roath et al. ( , 1963 (Hitchings and Elion, 1963) .
Timing was also found to be important by Tata (1964) , who showed that thalidomide is toxic to the tadpole for a short period in metamorphosis. It therefore seems likely that thalidomide might act only at a particular time in cell division.
Because it is spar-ngly soluble in aqueous media and because of its instability the problem would be to 
